On the public citation graph

Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

0 signed · 158 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.jtho.2016.11.2228openalex-snapshot
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
inferredcites →https://doi.org/10.1016/j.jtho.2019.06.010openalex-snapshot
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
inferredcites →https://doi.org/10.1016/s0140-6736(13)61719-5openalex-snapshot
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(14)60845-xopenalex-snapshot
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(17)31046-2openalex-snapshot
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
inferredcites →https://doi.org/10.1016/s0140-6736(18)31257-1openalex-snapshot
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(19)30723-8openalex-snapshot
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)70420-6openalex-snapshot
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(18)30937-9openalex-snapshot
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30458-9openalex-snapshot
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
inferredcites →https://doi.org/10.1016/s2213-2600(19)30084-0openalex-snapshot
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
inferredcites →https://doi.org/10.1038/ncomms12624openalex-snapshot
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1809697openalex-snapshot
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
inferredcites →https://doi.org/10.1056/nejmoa1816714openalex-snapshot
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1080/14656566.2017.1369956openalex-snapshot
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies
inferredcites →https://doi.org/10.1093/annonc/mdw525.01openalex-snapshot
Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results
inferredcites →https://doi.org/10.1093/annonc/mdx514openalex-snapshot
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
inferredcites →https://doi.org/10.1093/annonc/mdz446.002openalex-snapshot
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-2443openalex-snapshot
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
inferredcites →https://doi.org/10.1186/s13000-016-0545-8openalex-snapshot
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
inferredcites →https://doi.org/10.1186/s13000-019-0873-6openalex-snapshot
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
inferredcites →https://doi.org/10.1186/s40425-018-0403-1openalex-snapshot
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.4071openalex-snapshot
Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.4032openalex-snapshot
Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.
inferredcites →https://doi.org/10.1200/jco.2019.37.15_suppl.4004openalex-snapshot
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
inferredcites →https://doi.org/10.1200/jco.2019.37.4_suppl.336openalex-snapshot
Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
inferredcites →https://doi.org/10.1371/journal.pone.0231936openalex-snapshot
Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5016626openalex-extracted
Vasculopathy in the Correa's Cascade of Gastric Cancer: Pathological Features and Phytotherapy Strategy
inferred← citeshttps://doi.org/10.1002/cam4.5676openalex-snapshot
The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD ‐1/ PD‐L1 inhibitors: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/cam4.6602openalex-snapshot
Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
inferred← citeshttps://doi.org/10.1002/cam4.71065openalex-snapshot
Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1002/cnr2.1794openalex-snapshot
PD ‐1/ PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level
inferred← citeshttps://doi.org/10.1002/kjm2.12401openalex-snapshot
Evolution of systemic treatment for advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/mc.23451openalex-snapshot
Molecular and immune targets in cutaneous squamous cell carcinoma
inferred← citeshttps://doi.org/10.1002/onco.13638openalex-snapshot
The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients
inferred← citeshttps://doi.org/10.1007/13905_2021_5openalex-snapshot
Perspective on the Immunotherapy of Gastric Cancer
inferred← citeshttps://doi.org/10.1007/978-3-032-24071-2_5openalex-snapshot
Precision Medicine in Gastric, Gastroesophageal, Pancreatic, and Biliary Tract Tumors
inferred← citeshttps://doi.org/10.1007/s00228-025-03820-yopenalex-snapshot
Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00432-022-04057-3openalex-snapshot
Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s10238-022-00873-6openalex-snapshot
Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s10238-023-01104-2openalex-snapshot
Immunology and immunotherapy in gastric cancer
inferred← citeshttps://doi.org/10.1007/s11096-025-02055-2openalex-snapshot
Bibliometric analysis of anti-angiogenic therapy in gastric cancer: research hotspots, trends, and emerging frontiers
inferred← citeshttps://doi.org/10.1007/s11864-021-00886-5openalex-snapshot
Immunotherapy in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s11912-021-01099-7openalex-snapshot
Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors
inferred← citeshttps://doi.org/10.1007/s12094-023-03181-xopenalex-snapshot
Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway
inferred← citeshttps://doi.org/10.1007/s12254-022-00796-8openalex-snapshot
A GLOBAL DIGEST ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO Immuno-Oncology Congress, 8th – 11th December 2021
inferred← citeshttps://doi.org/10.1007/s12325-022-02371-3openalex-snapshot
Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1016/b978-0-323-90190-1.00007-xopenalex-snapshot
Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.bbcan.2021.188615openalex-snapshot
Advances in clinical immunotherapy for gastric cancer
inferred← citeshttps://doi.org/10.1016/j.bcp.2025.117574openalex-snapshot
Tumor vasculature–mediated formation of tertiary lymphoid structures: unraveling spatiotemporal coupling to optimize vasculo-immunotherapy
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.104070openalex-snapshot
Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102280openalex-snapshot
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.drup.2026.101468openalex-snapshot
Consensus on standardized later-line systemic therapy for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102376openalex-snapshot
Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)
inferred← citeshttps://doi.org/10.1016/j.ejim.2022.12.025openalex-snapshot
Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.108135openalex-snapshot
Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.108322openalex-snapshot
Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110001openalex-snapshot
EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110785openalex-snapshot
Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2023.107353openalex-snapshot
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.radmp.2022.07.005openalex-snapshot
Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy
inferred← citeshttps://doi.org/10.1016/j.semcancer.2025.01.007openalex-snapshot
Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies
inferred← citeshttps://doi.org/10.1016/j.soc.2023.03.004openalex-snapshot
A Review of Advances in Radiotherapy in the Setting of Esophageal Cancers
inferred← citeshttps://doi.org/10.1021/acsptsci.4c00677openalex-snapshot
Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease’s Origins, Epidemiology, Classification, Diagnosis, and Treatment Options
inferred← citeshttps://doi.org/10.1038/s41417-021-00310-yopenalex-snapshot
Recent advances in immune therapies for gastric cancer
inferred← citeshttps://doi.org/10.1038/s41575-022-00704-9openalex-snapshot
Evolving therapeutic landscape of advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1038/s41598-025-08388-2openalex-snapshot
In Silico tool for predicting, designing and scanning IL-2 inducing peptides
inferred← citeshttps://doi.org/10.1080/07853890.2022.2048416openalex-snapshot
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
inferred← citeshttps://doi.org/10.1080/13543784.2021.1940948openalex-snapshot
Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver
inferred← citeshttps://doi.org/10.1080/13543784.2022.2033208openalex-snapshot
Durvalumab: an investigational agent for unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/14712598.2024.2395921openalex-snapshot
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma
inferred← citeshttps://doi.org/10.1080/14737140.2023.2238896openalex-snapshot
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1080/14740338.2022.1995353openalex-snapshot
Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein
inferred← citeshttps://doi.org/10.1080/2162402x.2023.2214478openalex-snapshot
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1097/cm9.0000000000002768openalex-snapshot
Advances in targeted therapy and immunotherapy for esophageal cancer
inferred← citeshttps://doi.org/10.1097/cm9.0000000000003060openalex-snapshot
Immunotherapy for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1097/coc.0000000000001375openalex-snapshot
Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor–Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma
inferred← citeshttps://doi.org/10.1097/js9.0000000000003918openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6529953openalex-snapshot
Data from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-2821openalex-snapshot
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
inferred← citeshttps://doi.org/10.1159/000526638openalex-snapshot
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000528698openalex-snapshot
Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1177/15330338221150555openalex-snapshot
Research Progress of Immunotherapy for Gastric Cancer
inferred← citeshttps://doi.org/10.1177/17562848261439234openalex-snapshot
Advancements in targeted therapy for gastric cancer
inferred← citeshttps://doi.org/10.1177/17588359221110176openalex-snapshot
Tumor vessel normalization and immunotherapy in gastric cancer
inferred← citeshttps://doi.org/10.1186/s12885-021-08858-6openalex-snapshot
Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study
inferred← citeshttps://doi.org/10.1186/s12885-023-11678-5openalex-snapshot
Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1186/s12885-025-13591-5openalex-snapshot
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
inferred← citeshttps://doi.org/10.1186/s12935-022-02760-2openalex-snapshot
Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s12935-025-03655-8openalex-snapshot
A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies
inferred← citeshttps://doi.org/10.1186/s12964-022-00838-yopenalex-snapshot
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
inferred← citeshttps://doi.org/10.1186/s13045-021-01034-0openalex-snapshot
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
inferred← citeshttps://doi.org/10.1186/s13046-021-02053-yopenalex-snapshot
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
inferred← citeshttps://doi.org/10.1186/s13046-023-02861-4openalex-snapshot
Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming
inferred← citeshttps://doi.org/10.1186/s43046-023-00192-1openalex-snapshot
Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing trials
inferred← citeshttps://doi.org/10.1245/s10434-025-17386-7openalex-snapshot
The Evolving Role of Immunotherapy for Gastroesophageal Malignancies
inferred← citeshttps://doi.org/10.12677/acm.2023.135993openalex-snapshot
Research Progress of PD-1/PD-L1 Inhibitors in the Treatment of Advanced Gastric Carcinoma
inferred← citeshttps://doi.org/10.12677/jcpm.2024.32046openalex-snapshot
Therapeutic Immunomodulation of Gastric Cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0323023openalex-snapshot
Hepatotoxicity of ICI monotherapy or combination therapy in HCC: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.21037/tcr-22-2906openalex-snapshot
In silico trials of combination immuno-radiation for unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.21147/j.issn.1000-9604.2023.02.02openalex-snapshot
When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road
inferred← citeshttps://doi.org/10.21203/rs.3.rs-175261/v1openalex-snapshot
Mining the TCGA Database for Microenvironment‐Related Genes with Prognostic Value in Gastric Cancer
inferred← citeshttps://doi.org/10.2147/cmar.s335543openalex-snapshot
AGTR1 Inhibits the Progression of Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.2147/cmar.s537930openalex-snapshot
Angiogenesis and Immunosuppressive Niche in Hepatocellular Carcinoma: Reshaping Vascular - Immune Axis to Potentiate antiPD - 1/PD - L1 Therapy
inferred← citeshttps://doi.org/10.2147/itt.s253581openalex-snapshot
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
inferred← citeshttps://doi.org/10.2147/jhc.s322289openalex-snapshot
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.2147/ott.s268309openalex-snapshot
Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
inferred← citeshttps://doi.org/10.2174/1386207326666230808112656openalex-snapshot
Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.2174/1389450124666230330101651openalex-snapshot
The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors
inferred← citeshttps://doi.org/10.2217/fon-2022-0281openalex-snapshot
The Clinical Position of Ramucirumab-Containing Regimens for Advanced Gastric Cancer: A Review of Clinical Trial Data
inferred← citeshttps://doi.org/10.2217/imt-2022-0080openalex-snapshot
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer
inferred← citeshttps://doi.org/10.2217/imt-2022-0089openalex-snapshot
Surrogate end Points for Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.3233/thc-231876openalex-snapshot
Analysis of clinical efficacy and long-term prognosis of patients with hepatocellular carcinoma treated with PD-L1 inhibitor targeting
inferred← citeshttps://doi.org/10.32604/or.2024.052207openalex-snapshot
Immunotherapy in gastric cancer—A systematic review
inferred← citeshttps://doi.org/10.3389/fcell.2021.684966openalex-snapshot
Targeting the Microenvironment in Esophageal Cancer
inferred← citeshttps://doi.org/10.3389/fcell.2021.817085openalex-snapshot
Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.3389/fimmu.2021.712351openalex-snapshot
Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1059331openalex-snapshot
Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review
inferred← citeshttps://doi.org/10.3389/fimmu.2022.802846openalex-snapshot
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1218258openalex-snapshot
The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1265865openalex-snapshot
Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1358306openalex-snapshot
The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1487610openalex-snapshot
Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1742723openalex-snapshot
Unlocking the potential: current landscape and future directions of immunotherapy in gastric cancer
inferred← citeshttps://doi.org/10.3389/fonc.2021.699060openalex-snapshot
Application of Immunotherapy in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2021.719896openalex-snapshot
Advances of Targeted Therapy for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2022.1021772openalex-snapshot
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
inferred← citeshttps://doi.org/10.3389/fonc.2022.905520openalex-snapshot
Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
inferred← citeshttps://doi.org/10.3389/fonc.2022.934249openalex-snapshot
Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review
inferred← citeshttps://doi.org/10.3389/fonc.2022.964779openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
inferred← citeshttps://doi.org/10.3389/fonc.2022.993573openalex-snapshot
Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2023.1137224openalex-snapshot
Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
inferred← citeshttps://doi.org/10.3389/fonc.2023.1172292openalex-snapshot
Recent advances in oncolytic virus therapy for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3389/fphar.2022.920165openalex-snapshot
Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies
inferred← citeshttps://doi.org/10.3390/biomedicines13010006openalex-snapshot
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
inferred← citeshttps://doi.org/10.3390/cancers13081922openalex-snapshot
Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3390/cancers13143536openalex-snapshot
How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
inferred← citeshttps://doi.org/10.3390/cancers15112996openalex-snapshot
Immunotherapy through the Lens of Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3390/cancers16030560openalex-snapshot
Therapeutic Immunomodulation in Gastric Cancer
inferred← citeshttps://doi.org/10.3390/cancers16081582openalex-snapshot
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges
inferred← citeshttps://doi.org/10.3390/curroncol30100633openalex-snapshot
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
inferred← citeshttps://doi.org/10.3390/jcm10122662openalex-snapshot
Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3390/jcm12093226openalex-snapshot
The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review
inferred← citeshttps://doi.org/10.3390/molecules29133002openalex-snapshot
Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases
inferred← citeshttps://doi.org/10.3748/wjg.v30.i8.779openalex-snapshot
Immunotherapy of gastric cancer: Present status and future perspectives
inferred← citeshttps://doi.org/10.4103/jcrt.jcrt_1031_23openalex-snapshot
Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.4251/wjgo.v15.i1.143openalex-snapshot
Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer
inferred← citeshttps://doi.org/10.51731/cjht.2021.145openalex-snapshot
Durvalumab (Imfinzi)
inferred← citeshttps://doi.org/10.5387/fms.25-00009openalex-snapshot
Development of combinatorial immunotherapy for patients with advanced gastric cancer from the perspective of immunosuppressive mechanisms in the tumor microenvironment
inferred← citeshttps://doi.org/10.5603/njo.2021.0073openalex-snapshot
Management of hepatocellular carcinoma with novel immunotherapeutic agents and prospects for the future
inferred← citeshttps://doi.org/10.5603/njo.a2022.0043openalex-snapshot
Immunotherapeutics and other anticancer agents in the management of advanced gastric cancer
inferred← citeshttps://doi.org/10.5662/wjm.v13.i3.79openalex-snapshot
Immunotherapy for advanced gastric cancer
inferred← citeshttps://doi.org/10.5772/intechopen.1015672openalex-snapshot
Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: Recent Advances
inferred← citeshttps://doi.org/10.6084/m9.figshare.21592463openalex-snapshot
Additional file 1 of Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26628775openalex-snapshot
Additional file 1 of Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming
inferred← citeshttps://doi.org/10.6084/m9.figshare.26628778openalex-snapshot
Additional file 2 of Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming
inferred← citeshttps://doi.org/10.6084/m9.figshare.26628781openalex-snapshot
Additional file 3 of Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.